It would be amiss to go into the New Year without recognising that 2025 was a big year for Robeauté. Here’s a rewind of a few highlights and our favourite pinch-us moments.

From France, to the World

In January 2025 we closed a €27M series A, which welcomed a new group of investors aboard our mission: Plural, Cherry, Local Globe, Kindred and Think+Health.

Learn more about us →

With that, we will be strengthening our team through new hires in core positions and continuing to grow significantly throughout 2026.

{{careers-cta}}

Three of our joint PhD students completed their thesis on critical subjects such as medical imagining, micro-navigation and alternative propulsion mechanisms and joined our ranks full-time. Their work is remarkable and foundational to our technology. We are now 33, from over 10 countries.

On top of the equity funding, Robeauté also secured European and French national non-dilutive funding after competitive selection and thorough due diligence. And we're particularly proud that Robeauté was officially recognised in the “French Tech 2030” cohort, as one of 80 disruptors helping accelerate the emergence of global champions from France.

Along the way, we've been grateful for opportunities to tell our story and share our mission to a wider audience, around the world and help more people understand that microrobotics for the brain is no longer sci-fi:

• ‍Fortune: Exclusive: Startup pioneering tiny robots that can travel inside the brain gets $28 million in new venture funding‍
• Bloomberg: European Brain Surgery Startup Seeks US Expansion‍
• The Independent: Robots the size of grain of rice that can travel through brain to carry out surgery‍
• The Times: Tech’s Rising Stars‍
• R&D World: Rice-sized robot could rewrite the neurosurgery playbook‍
• Bpifrance: Robeauté : taille minimale, ambitions maximales

Strong progress in engineering and pre-clinical testing

The team continued to validate our microrobot in pre-clinical settings, and spent countless hours building bridges with the medical community of surgeons, clinicians, researchers and regulators across US and Europe ahead of the next pivotal phase of development.

Learn more about our technology →

• ‍We made significant progress on the design of the microrobot to miniaturise it down to our current and final size of 1.8mm in diameter. Every step required repeated design, multi-physical modelling, fabrication, micro-assembly, test, iteration and optimisation – on repeat – and gave rise to new proprietary patents.‍
• The team has been hard at work on all the different components of the overall system that enable the microrobot to operate seamlessly: our in-house extensions for advanced tissue biopsy and drug-delivery, the CAP, comprised of the launcher and tracking system, MOM our console and proprietary software. Each element is reviewed, challenged and optimised in close collaboration with our world-class medical board.‍
• On the data and software side, we are redefining not only minimally-invasive brain surgery but brain therapies at large  – to be informed and enabled by an entirely new data-set comprised of site-specific and patient specific live data. This is particularly valuable to pharmaceutical companies developing novel therapeutics for brain disease. Today it’s a $72B market and very few treatments actually work (and when they do we don’t entirely know why).

Future of neurotechnology on global stage

2025 was a year of much travel for the team – to medical and industry conferences and stages, to partner sites and clinical facilities that strengthened our mission. Joana brought Robeauté to one of the most iconic venues in Paris for TEDx PARIS and the team showed up at The Medtech Conference, Congress of Neurological Surgeons, Society for Neuro-Oncology to SXSW London, Italian Tech Week and Slush among many others.

In July we hosted the second edition of the annual Brain Gardeners’ Club in Paris, a salon-like day of conferences with surgeons, scientists, innovators and cross-disciplinary thinkers from around multiple countries, in partnership with the AP-HP University Hospital Group and a line-up of exceptional speakers discussing the brain, neuro-health and building for medical impact.

Looking ahead: proving the clinical microrobotic approach

2026 will be an equally pivotal year as we continue advancing towards first-in-human patient trials with longstanding trusted partners to prove the clinical microrobotic approach and usher in a new dawn in the treatment of brain disease.

Alongside Europe, our presence in the US is of strategic importance to support clinical trials and market access – more on that soon! We’ll also continue to invest in our roots and R&D capabilities in Paris by expanding the footprint in a new space that will integrate our own white room, medical OR and manufacturing line.

As this new year begins and the speed of innovation and technological progress continues to outpace the human mind, we hold firmly onto our values – grateful to be given the privilege to build something, once deemed impossible, to cure loved ones and redefine care.

Onwards – with rigour, humility and a pinch of punk.